Malignant Mesothelioma - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 547
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M07150376F6EN
Leaflet:

Download PDF Leaflet

Malignant Mesothelioma - Pipeline Review, H2 2017
Malignant Mesothelioma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 34, 25, 15, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 6 and 6 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Malignant Mesothelioma - Overview
Malignant Mesothelioma - Therapeutics Development
Malignant Mesothelioma - Therapeutics Assessment
Malignant Mesothelioma - Companies Involved in Therapeutics Development
Malignant Mesothelioma - Drug Profiles
Malignant Mesothelioma - Dormant Projects
Malignant Mesothelioma - Discontinued Products
Malignant Mesothelioma - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Malignant Mesothelioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Malignant Mesothelioma - Pipeline by Aduro BioTech Inc, H2 2017
Malignant Mesothelioma - Pipeline by Advantagene Inc, H2 2017
Malignant Mesothelioma - Pipeline by AnGes MG Inc, H2 2017
Malignant Mesothelioma - Pipeline by arGEN-X BV, H2 2017
Malignant Mesothelioma - Pipeline by ArQule Inc, H2 2017
Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Biogen Inc, H2 2017
Malignant Mesothelioma - Pipeline by Bionomics Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Biotecnol Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H2 2017
Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2017
Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H2 2017
Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H2 2017
Malignant Mesothelioma - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Checkpoint Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Concordia International Corp, H2 2017
Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2017
Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2017
Malignant Mesothelioma - Pipeline by EpiZyme Inc, H2 2017
Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Malignant Mesothelioma - Pipeline by Five Prime Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Genelux Corp, H2 2017
Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2017
Malignant Mesothelioma - Pipeline by Horizon Pharma Plc, H2 2017
Malignant Mesothelioma - Pipeline by Inventiva, H2 2017
Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Malignant Mesothelioma - Pipeline by MacroGenics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Malignant Mesothelioma - Pipeline by MedImmune LLC, H2 2017
Malignant Mesothelioma - Pipeline by Merck & Co Inc, H2 2017
Malignant Mesothelioma - Pipeline by Merck KGaA, H2 2017
Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by MolMed SpA, H2 2017
Malignant Mesothelioma - Pipeline by Morphotek Inc, H2 2017
Malignant Mesothelioma - Pipeline by MTG Biotherapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Novartis AG, H2 2017
Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Malignant Mesothelioma - Pipeline by OSE Immunotherapeutics, H2 2017
Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2017
Malignant Mesothelioma - Pipeline by Pharma Mar SA, H2 2017
Malignant Mesothelioma - Pipeline by Philogen SpA, H2 2017
Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by Seattle Genetics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Selecta Biosciences Inc, H2 2017
Malignant Mesothelioma - Pipeline by Sorrento Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Targovax ASA, H2 2017
Malignant Mesothelioma - Pipeline by Tesaro Inc, H2 2017
Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Malignant Mesothelioma - Pipeline by TREAT U SA, H2 2017
Malignant Mesothelioma - Pipeline by UbiVac LLC, H2 2017
Malignant Mesothelioma - Pipeline by VasGene Therapeutics Inc, H2 2017
Malignant Mesothelioma - Pipeline by Verastem Inc, H2 2017
Malignant Mesothelioma - Pipeline by Vyriad Inc, H2 2017
Malignant Mesothelioma - Pipeline by Y's Therapeutics Co Ltd, H2 2017
Malignant Mesothelioma - Dormant Projects, H2 2017
Malignant Mesothelioma - Dormant Projects, H2 2017 (Contd..1), H2 2017
Malignant Mesothelioma - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Malignant Mesothelioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Aduro BioTech Inc
Advantagene Inc
AnGes MG Inc
arGEN-X BV
ArQule Inc
AVEO Pharmaceuticals Inc
Biogen Inc
Bionomics Ltd
Biotecnol Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
CanBas Co Ltd
CBT Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Concordia International Corp
Eagle Pharmaceuticals Inc
Eli Lilly and Company
EnGeneIC Ltd
EpiZyme Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genelux Corp
GlaxoSmithKline Plc
Horizon Pharma Plc
Inventiva
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Laboratoires Pierre Fabre SA
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MolMed SpA
Morphotek Inc
MTG Biotherapeutics Inc
Novartis AG
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics
Oxford BioMedica Plc
Pharma Mar SA
Philogen SpA
Polaris Pharmaceuticals Inc
Seattle Genetics Inc
Selecta Biosciences Inc
Sorrento Therapeutics Inc
Targovax ASA
Tesaro Inc
TRACON Pharmaceuticals Inc
TREAT U SA
UbiVac LLC
VasGene Therapeutics Inc
Verastem Inc
Vyriad Inc
Y's Therapeutics Co Ltd
Skip to top


Malignant Pleural Mesothelioma - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 315 pages
Recurrent Malignant Glioma - Pipeline Review, H2 2016 US$ 2,000.00 Dec, 2016 · 45 pages
Recurrent Malignant Glioma - Pipeline Review, H1 2017 US$ 2,000.00 Jun, 2017 · 40 pages
Malignant Glioma - Pipeline Review, H2 2015 US$ 2,000.00 Jul, 2015 · 116 pages

Ask Your Question

Malignant Mesothelioma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: